canyon landscape

Ribociclib (LEE011) in Preoperative Glioma and Meningioma Patients

In the proposed trial, patients will be administered ribociclib prior to surgical resection of their tumor. Patients will be enrolled in time-intervals sequentially (non-randomized). All patients will be orally-administered 5 doses of LEE011 (900 mg/d) with the final dose occurring at one of 3 intervals before brain tumor resection.

Open and enrolling subjects.
Phoenix, Arizona
Total Participants
Primary Sponsor
Nader Sanai, MD
Additional Sponsor(s)
Ivy Brain Tumor Center
Barrow Neurological Institute